<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04903223</url>
  </required_header>
  <id_info>
    <org_study_id>STUDY00001550</org_study_id>
    <nct_id>NCT04903223</nct_id>
  </id_info>
  <brief_title>Liver Adiposity Effects on Pediatric Statin</brief_title>
  <official_title>Effects of Pediatric Liver Adiposity on Statin Disposition and Response</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Children's Mercy Hospital Kansas City</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Children's Mercy Hospital Kansas City</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Single center, open-label, prospective investigation to quantify the effects hepatocellular&#xD;
      fat has on hepatic statin transport and response in children and adolescents in obese and&#xD;
      non-obese children and adolescents 8-21 years of age with normal, wild-type SLCO1B1 c.521TT&#xD;
      genotype that are dosed rosuvastatin&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 1, 2021</start_date>
  <completion_date type="Anticipated">November 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">November 1, 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>This is a single center, open-label, prospective, investigation to quantify the effects hepatocellular fat has on hepatic statin transport (SA1) and response (SA2) in children and adolescents.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluate effect of Liver Fat Percentage (on MRI) on AUC</measure>
    <time_frame>2 years</time_frame>
    <description>We expect that increased liver adiposity will be associated with higher systemic statin exposure and thus, place those with higher liver adiposity fraction at increased risk for drug toxicity.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluate effect of Liver Fat Percentage (on MRI) on change on plasma mevalonate level</measure>
    <time_frame>2 years</time_frame>
    <description>We expect that increased liver adiposity will be associated with an attenuated mevalonate response to a statin in obese children placing those with increased liver adiposity at risk for treatment failure.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Cholesterol; Lipidosis</condition>
  <arm_group>
    <arm_group_label>Baseline Mevalonate and MRI Imaging</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Mevalonate Change After Rosuvastatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rosuvastatin 10mg</intervention_name>
    <description>Rosuvastatin will be administered to all participants on Study Day #2</description>
    <arm_group_label>Mevalonate Change After Rosuvastatin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  8-21 years&#xD;
&#xD;
          -  LDL cholesterol &gt;130mg/dl (&gt;95% percentile)&#xD;
&#xD;
          -  SLCO1B1 c.521TT genotype&#xD;
&#xD;
          -  Provide informed permission-assent(&lt;18 yrs.) or consent (≥18 yrs.)&#xD;
&#xD;
          -  Fasting overnight (~8 hrs.)&#xD;
&#xD;
          -  Enrolled in Cardiology Pharmacogenomic Repository&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Non-fasting&#xD;
&#xD;
          -  Non-removable metal in body or MRI unsafe&#xD;
&#xD;
          -  Currently on or history of statin therapy&#xD;
&#xD;
          -  Underlying congenital or acquired hemodynamically CV disease&#xD;
&#xD;
          -  History of underlying or laboratory evidence of underlying intestinal, metabolic,&#xD;
             autoimmune, renal disease that can alter rosuvastatin disposition * (absorption,&#xD;
             metabolism, distribution, or clearance)&#xD;
&#xD;
          -  Pharmacotherapy that interact with statins (OATP1B1 inducers/inhibitors) *&#xD;
&#xD;
          -  Inability to swallow a tablet&#xD;
&#xD;
             •&gt;3x the age-specific upper limit of normal for AST, ALT, total and conjugated&#xD;
             bilirubin&#xD;
&#xD;
          -  Diarrhea in the last 24 hours&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>8 Years</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jonathan Wagner, DO</last_name>
    <phone>816-731-7240</phone>
    <email>jbwagner@cmh.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Children's Mercy Hospital</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64108</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jonathan B Wagner, DO</last_name>
      <phone>816-234-3000</phone>
      <phone_ext>59373</phone_ext>
      <email>jbwagner@cmh.edu</email>
    </contact>
    <investigator>
      <last_name>Jonathan B Wagner, DO</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 17, 2021</study_first_submitted>
  <study_first_submitted_qc>May 22, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 26, 2021</study_first_posted>
  <last_update_submitted>October 26, 2021</last_update_submitted>
  <last_update_submitted_qc>October 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lipidoses</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rosuvastatin Calcium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

